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1. Expanded methods section 
Clinical investigations 
Clinical investigations included family history, 12-lead electrocardiogram, 2D-doppler 
transthoracic echocardiography, 48-hour Holter-monitoring, and signal-averaged 
electrocardiogram. Cardiac magnetic resonance imaging, coronary angiogram, right 
ventricular cine angiography, histological examination of right ventricular endomyocardial 
biopsies, and electrophysiological studies was performed in the majority of index-patients, 
and the results hereof were evaluated according to 2010 ARVC diagnostic criteria (1). The 
relatives underwent a non-invasive screening program, and if ARVC was suspected, they 
proceeded to cardiac magnetic resonance imaging and subsequently to invasive studies. Left 
ventricular dysfunction was defined as left ventricular ejection fraction ≤ 50%. Ventricular 
tachycardia was defined as 3 or more consecutive ventricular beats with a frequency >120 
beats per minute. 
 
Genetic investigations 
Mutation analysis of the 5 ARVC-related genes encoding desmosomal proteins: desmoplakin 
(DSP, NM_004415.2), plakoglobin (JUP, NM_021991.2), plakophilin-2 (PKP2, 
NM_004572.3), desmoglein-2 (DSG2, NM_001943.3), and desmocollin-2 (DSC2, 
NM_024422.3) was performed by direct sequencing in all probands.(2) Genomic DNA was 
isolated from whole blood collected in EDTA-containing tubes using the Gentra Puregene 
Blood Kit (Qiagen). Polymerase chain reactions (PCR) were performed using sets of forward 
and reverse oligonucleotide primers designed to amplify all exons including a minimum of 10 
nucleotides flanking the exon-intron borders. Sense and antisense primers were modified 
with M13 sequences (M13-forward: GTAAAACGACGGCCAG, and M13-reverse: 
CAGGAAACAGCTATGAC) to use one primer set for the sequencing reaction of all 
amplicons. Primer sequences are available on request. 
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The quality of the PCR products was assessed by electrophoresis in 2% agarose gels 
and the amplicons were purified with S-400 MicroSpin columns (GE Healthcare) and 
sequenced in both directions using the BigDye Terminator version 1.1 Cycle sequencing kit 
(Applied Biosystems) followed by separation of the ethanol-precipitated fragments on an 
Applied Biosystems 3130 Genetic Analyzer. A PGem plasmid with a known nucleotide 
sequence was used as a positive control. The sequence traces were aligned to reference 
sequences (see above) using SeqScape (version 2.5, Applied Biosystems). All mutations 
were verified by bidirectional sequencing, and the results were confirmed using a second 
independent blood sample. 
 
Cultivation of primary keratinocytes 
Skin biopsies (Ø=4mm) were obtained from mutation carriers and wild type family members, 
and primary keratinocytes were harvested and cultured as previously described using a 
protocol based on the method initially described by Rheinwald and Green (3, 4). 
After application of intra-cutaneous infiltration analgesia with lidocaine 20 mg/ml the 
biopsies were excised and washed in phosphate-buffered-saline (PBS [80 mM 
Na2HPO4 2H20, 20 mM NaH2PO4 H20 PBS, 100 mM NaCl, pH 7.5]). The dermal part of 
the biopsies was trimmed off and the remaining part of the biopsies with the epidermal layer 
was placed at 37°C in a trypsin solution (0.25% trypsin in Hank’s balanced salt solution 
[Gibco] supplemented with 25 mM D-glucose). Trypsination was blocked after 2 hours by 
addition fetal calf serum (Gibco). The dislodged keratinocytes were pelleted and transferred 
to 9 ccm culture flasks and grown on a confluent layer of γ-irradiated J2 3T3 mouse fibroblast 
feeder cells in a humidified incubator (5% CO2, 37°). The culture media consisted of 
Dulbecco’s modified Eagle’s media (Gibco) with 22.5% (v/v) Ham’s F12 Nutrient mixture 
(Gibco), 10% (v/v) fetal calf serum (Gibco), 5 µg/ml insulin, 0.1 nM cholera toxin, 0.18 mM 
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adenine hydrochloride, 10 ng/ml human epidermal growth factor, 0.4 µg/ml hydrocortisone, 
100 IU/ml penicillin, and 0.1 mg/ml streptomycin (all purchased from Invitrogen). When the 
keratinocytes had reached 80-90% confluence, the feeder cells were dislodged with 0.02% 
EDTA-PBS and the primary keratinocytes were treated with trypsin (0.05% trypsin in 0.02% 
EDTA-PBS) for 20 min and sub-cultivated in large culture flasks with CNT-57 Epidermal 
Keratinocyte Media (CELL’n’TEC) supplemented with 5 µg/ml gentamicine. 
The formation of desmosomes in confluent keratinocyte monolayers was induced by 
raising the concentration of calcium chloride in the culture media from 0.07 mM to 1.25 mM 
(5). The cells were harvested 48 hours later in ice-cold PBS by use of a cell scraper and 
stored at -80°C until further processing. Third passage cells where used in all experiments. 
 
Western blotting 
For western blotting and protein mass spectrometry experiments cytoskeletal and 
cytoplasmic protein fractions from cultured keratinocytes were isolated by sequential 
detergent lysis.(5) Pellets of frozen keratinocytes were thawed and kept on ice. The cells 
were lysed (100 mM NaCl, 50 mM Tris-HCl, 1 mM DTT, 1% Triton- X-100, pH 7.4, protease 
inhibitor cocktail [Roche]) and sonicated. Soluble and insoluble protein fractions were 
separated by centrifugation (20000xg, 30 min, 4° C) and the pelleted insoluble protein 
fraction containing desmosomal proteins was dissolved in lysisbuffer with 8 M urea added. 
Total protein concentrations were determined with the Bradford Protein assay (Bio-Rad). 
Equal total protein amounts of extracted proteins diluted in SDS-sample buffer (60 mM Tris-
HCl, pH 6.8, 100 mM dithiothreitol, 2% (w/v) SDS, 0.01% bromophenolbue, 10% glycerol) 
were separated by sodium-docedyl-sulphate polyacrylmide gel electrophoresis (SDS-PAGE) 
with 4-12% Bis-tris XT-criterion gels (Biorad) and transferred to polyvinyledine-membranes 
(Immobilon-FL) by wet transfer technique (100V, 1h, 4°C, in 25 mM Tris-base, 192 mM 
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glycine, 0.1% SDS, 20% ethanol, pH 8.3).(6) After 1 hour of blocking in 5% skimmed fat milk 
in PBS, the blots were incubated overnight with primary antibodies and subsequently for 1 
hour with fluorescent secondary antibodies (IgG-Alexa Flour-488 or -635 from Invitrogen). 
Protein bands were visualized on a Storm Molecular Imager 840 (GE Healthcare) and band 
intensities were quantified with ImageQuant TL software (GE Healthcare). All blots included a 
dilution series, which allowed quantification of the target protein relative to loading control 
protein (beta-actin) by standard curve equations. All blotting experiments were made in 
triplicates. 
 
Nano-liquid chromatography coupled with tandem mass spectrometry (nLC-MS) 
Nano-liquid chromatography coupled with tandem mass spectrometry was used to estimate 
the expression of WT and mutant DSP protein present in the cytoskeleton of cultured 
keratinocytes. A previously published protocol was used with minor modifications (7). 
Cytoskeletal protein fractions extracted from cultured keratinocytes were separated by SDS-
PAGE as described above and the 250 kD gel fragments containing DSP1 were isolated 
from Coomassie stained gels. The gel pieces were destained in 0.025 mM 
ammoniumbicarbonate (NH4HCO3) in 50% acetonitrile, and the proteins were reduced (50 
mM TCEP [tris(2-carboxyethyl)phosphine] in 0.025 mM NH4HCO3,), and alkylated (100 mM 
iodoacetamide in 0.025 mM NH4HCO3) followed by in-gel proteolytic cleavage with trypsin 
(10 µg/ml in 0.025 mM NH4HCO3, Promega) for 16 hours at 37°C. 
The resulting tryptic peptides were purified with Pep-Clean C18 spin columns (Thermo 
Fischer) and analyzed with nano-liquid chromatography (Easy nLC, Proxeon, Denmark) 
coupled to tandem mass spectrometry (LQT-Orbitrap, Thermo Fisher Scientific). The 
peptides were eluted from the reverse phase column (3.5 µm Kromasil C18, Eka Chemicals, 
Sweden) by an acetonitrile, 0.4% acetic acid gradient; starting with 5% and ending with 35% 
acetonitrile. 
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Mass-to-charge ratios (m/z) of the peptides were analyzed by nLC-MS and identified by 
searching the MS data against an in-house IPI-human database (version 3.45 with 71994 
sequences) with DSP protein variants added. Mascot search engine 
(www.matrixscience.com) was used with full scan tolerance of 5 ppm and fragment ion 
tolerance of 1 Da, and maximal two missed trypsin cleavages. Relative quantification of 
peptides was performed through integration of their full scan peptide peaks by Genesis 
algorithm in Qual Browser software (Thermo Fisher Scientific). All experiments were made in 
triplicates. 
The following predicted DSP peptides were all identified (p-value <10-5) by nLC-MS and 
were subject to study:  
YEVTSGGGGTSR (DSP-WT, amino acid 28-39, m/z 585.6565);  
YEMTSGGGGTSR (DSP-V30M, amino acid 28-39, m/z 601.7517);  
AELIVQPELK (ref. peptide 1, DSP-WT, amino acid 85-94, m/z 570.3299);  
YGDGIQLTR (ref. peptide 2, DSP-WT, amino acid 95-103, m/z 511.7596);  
GQSEADSDKNATILELR (DSP-R1738Q, amino acid 1737-1753, m/z 616.3023). 
 
Immunohistochemistry (IHC)  
Immunohistochemistry of formalin-fixed paraffin-embedded myocardial and epidermal tissue 
was performed using standard techniques (6). Tissue sections from mutation-positive 
individuals and controls were mounted on the same slide and underwent the same staining 
procedures. Control tissue samples were epidermal biopsies collected of wild type family 
members and myocardial biopsies from the right ventricular septum obtained from deceased 
donors undergoing forensic autopsy (n=3, non-cardiac cause of death). 4 µm thick sections 
were dewaxed in xylene and rehydrated with decreasing concentrations of ethanol in water. 
Endogenous peroxidase activity was blocked in 3% (v/v) hydrogenperoxide for 10 minutes, 
and, next, the tissue sections were submersed overnight in Tris-EGTA-buffer (10 mM Tris-
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base, 0.5 mM EGTA, pH 9.0), 60°C, in order to induce heat-induced epitope retrieval. The 
specimens were cooled to ambient temperature and washed in PBS with 0.1% Triton X-100. 
Unspecific antibody binding was reduced by 30 minutes pre-incubation of the slides in 
blocking buffer (S3022, DAKO Cytomation), and afterwards, the slides were incubated 
overnight at 4°C with primary antibodies (se below) diluted in blocking buffer. Visualization 
was accomplished using a horseradish-peroxidase based detection system (EnVisionTM Flex, 
Dako Cytomation) according to manufacturer’s instructions. 
Microscopy was performed by two experienced cardiovascular pathologists who 
independently scored immuno-reactivity as normal, reduced or absent. The results of these 
observations were compared and if they were discordant consensus between the 
pathologists was obtained. 
 
Antibodies 
The following primary antibodies specific for different regions of DSP were used for WB: H-
300 (DSP1+2, epitope within 1-300 aa, Santa Cruz), DP447 (DSP1+2, epitope within 2714-
2731 aa, Progen). These antibodies were not applicable for IHC. Instead, DP236.23.1 
(DSP1+2, epitope within aa 1980-2871, Progen), and DP2.17 (DSP1, epitope within aa 1195-
1793, Progen) were used. Other antibodies used were: PKP2 (multiepitope cocktail, Progen), 
DSG2 (10G11, Progen), and beta-actin (C4, Santa Cruz) antibodies. Dilutions are available 
on request. 
 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was extracted from pellets of harvested keratinocytes (SV total RNA kit, 
Promega), and first-strand complementary DNA (cDNA) was synthesized from 500 ng RNA 
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with the Superscript III reverse transcriptase PCR Kit (Invitrogen) and oligo(dT)n+18 primers 
according to manufacturer’s instructions. Only RNA with an optical density ratio(A260/A280 nm) 
above 1.8 was used. DSP expression was estimated using TaqMan probes (Applied 
Biosystems) annealing to either the DSP1 transcript (assay no. Hs00950584_m1) or both 
DSP transcripts (assay no. Hs00950581_m1). Relative gene expression was calculated by 
the standard curve method and the expression of DSP1 and DSP was normalized to 
expression of the beta-actin gene (7). Each RT-PCR experiment was conducted 3 times 
using cell pellets from 3 independent cell cultures. 
In family 2, the amount of the mutant c.3805C>T DSP1 mRNA transcript was estimated 
using a TaqMan allelic discrimination SNP assay (Applied Biosystems) with probes 
annealing to either the WT DSP1 (5’-CAGCTCGCCTTCGC-3’-VIC) or the c.3805C>T mutant 
DSP1 (5’-TTCAGCTCACCTTCGC-3’-FAM) sequences. Forward and reverse primer 
sequences were 5’-GCATCTTGCAGGCCACTGA-3’ and 5’-CCACAGGCCTTTTGCTGAAG-
3’. Post-PCR fluorescent signal from cDNA and genomic DNA samples of WT and 
heterozygous mutation carriers was compared (7). Furthermore, genomic DNA and cDNA 
from WT and heterozygous mutation carriers were amplified by PCR and the amplicons were 
sequenced in both directions (BigDye terminator v1.1, Applied Biosystems). 
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